One of the key issues described by many researchers is how to overcome the innovation gaps on the translational research pathway. This includes identifying barriers on which to concentrate, finding funding and meeting the right networks.
ON Helix is a must-attend translational research conference for the life science industry and academia. This one day event aims to inform delegates of how to turn early stage inventions and ideas into innovative health treatments. It will present the UK landscape of the business environment, funding, scientific and clinical research excellence and will be a unique knowledge-sharing environment between academia and business. It will combine keynote presentations from high profile global leaders, practical information, exceptional world class case studies and plenty of space for networking.
Why should I attend?
As the largest membership organisation in Europe for the sector, One Nucleus has very strong engagement with the life science and healthcare sector nationally and internationally so is perfectly placed to ensure the attendance and engagement of key stakeholders in translational research. The feedback both from our exceptional Advisory Board and widely throughout the business and academic community has been unanimously positive about this event – its concept, objectives and the platform it will create.
Who should attend?
- Biotech and healthcare company senior executives
- Academic technology transfer executives
- Pharma business and research development directors
- Life science investors
- Technical and professional service providers
- Scientists working in translational research or medicine
The following key-note speakers have been announced:
- Sharon Vosmek, CEO, Astia
- David Tapolczay, CEO, MRC Technology
- Sara-Jane Dunn, Microsoft
To view further information including the full event programme, delegate fees and how to regsiter, please click here.
*SPECIAL OFFER* Medilink members can receive a 10% off the standard ticket price; please contact us here for a discount code.